The term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection fraction is <50%. The prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the natural history remains incompletely characterized.
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry / Marstrand, P., Han, L., Day, S.M., Olivotto, I., Ashley, E.A., Michels, M., Pereira, A.C., Wittekind, S.G., Helms, A., Saberi, S., Jacoby, D., Ware, J.S., Colan, S.D., Semsarian, C., Ingles, J., Lakdawala, N.K., Ho, C.Y.. - In: CIRCULATION. - ISSN 0009-7322. - STAMPA. - 141:(2020), pp. 1371-1383-1383. [10.1161/CIRCULATIONAHA.119.044366]
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
Olivotto, Iacopo;
2020
Abstract
The term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection fraction is <50%. The prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the natural history remains incompletely characterized.
| File | Dimensione | Formato | |
|---|---|---|---|
|
CIRCULATIONAHA.119.044366.pdf
Open Access dal 01/01/2021
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.48 MB
Formato
Adobe PDF
|
1.48 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
